Clinical trial
A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of an Adeno-associated Viral Vector Containing an Expression Cassette of the Human Factor VIII Transgene (BBM-H803) Injection in Participants With Hemophilia A
NCT06111638 is registered in ClinicalTrials.gov with Shanghai Xinzhi BioMed Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of an Adeno-associated Viral Vector Containing an Expression Cassette of the Human Factor VIII Transgene (BBM-H803) Injection in Participants With Hemophilia A
- Lead sponsor
- Shanghai Xinzhi BioMed Co., Ltd.
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- January 3, 2024
- Completion date
- May 30, 2031
- Enrollment
- 55 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.